Educational  ·  Mechanism-Led

Tesamorelin (Egrifta), what the science actually shows

Tesamorelin is a synthetic GHRH analog FDA-approved for HIV-associated lipodystrophy. Evidence base: strong clinical data for the approved HIV lipodystrophy indication; general weight loss evidence is weaker.

An FDA-approved growth hormone-releasing hormone (GHRH) analog. Strong clinical data for reducing visceral fat in HIV-associated lipodystrophy. Increasingly used off-label in anti-aging clinics. The approved-use evidence is excellent. The anti-aging evidence is not.

44
Amino acids
FDA
Approved (lipodystrophy)
Split
Evidence rating
Scroll
On this page
  1. What Tesamorelin is. And where it comes from
  2. Mechanism, in plain English
  3. What the clinical evidence shows
  4. FDA status
  5. Common synonyms researchers use
  6. Safety and adverse-event landscape
  7. Frequently asked questions
Mechanism
GHRH analog that stimulates pituitary growth hormone release. Reduces visceral adipose tissue. Increases IGF-1 levels.
Evidence Level
Split rating: ★★★★★ for FDA-approved indication (HIV lipodystrophy). ★★★☆☆ for off-label anti-aging use.
FDA Status
FDA-approved as Egrifta for HIV-associated lipodystrophy. Prescription required. Off-label anti-aging use is physician-directed.
Landmark Paper
Falutz et al. 2007, JAMA
Common Synonyms
Tesamorelin, Egrifta, TH9507, GHRH(1-44)NH2, growth hormone-releasing factor analog
Last Reviewed
August 19, 2026

What Tesamorelin is. And where it comes from

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that tells your pituitary gland to produce growth hormone. It is a 44-amino-acid peptide, identical to natural GHRH(1-44) with a trans-3-hexenoic acid modification that improves stability.

It was developed by Theratechnologies and approved by the FDA in 2010 as Egrifta for the reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy. A condition where antiretroviral drugs cause abnormal fat redistribution.

In recent years, tesamorelin has gained traction in anti-aging and functional medicine clinics as a GH-axis stimulator for body composition improvement, cognitive function, and general healthspan. This off-label use has a different evidence basis than the approved indication.

Tesamorelin is a rare case in the peptide world: an actually FDA-approved compound with strong RCT data. But the approval is for HIV lipodystrophy, not anti-aging. The off-label jump is common in medicine, but the evidence gap is real.

Peptexa editorial note

Mechanism, in plain English

Tesamorelin works through the growth hormone axis with a well-characterized mechanism.

GHRH
Mimics natural GHRH, stimulates pituitary growth hormone release in a pulsatile pattern
GH
Increases growth hormone secretion, without the supraphysiological spikes of direct GH injection
VAT
Reduces visceral adipose tissue, the metabolically dangerous deep abdominal fat
IGF-1
Raises IGF-1 levels, downstream effector of growth hormone signaling

Want all 32 Anti-Aging & Longevity compounds in one place?

The Peptexa Anti-Aging & Longevity guide covers every compound in this category, mechanism, evidence level, and regulatory status for each.

Get the Guide →

What the clinical evidence shows

For HIV lipodystrophy (★★★★★): Multiple large randomized controlled trials support the approved indication. The LIPO-015, LIPO-016, and LIPO-024 trials showed statistically significant reduction in visceral fat (trunk fat reduced ~15-18%) versus placebo. This is strong, replicated clinical evidence.

For anti-aging / body composition (★★★☆☆): Some data from the HIV trials and smaller studies suggest cognitive benefits, improved body composition in non-HIV populations, and favorable metabolic markers. However, no large RCT has been conducted specifically for anti-aging or general wellness use in healthy adults.

For cognitive function: A secondary analysis of tesamorelin trial data and a small dedicated study suggest improved executive function and verbal memory. Promising but preliminary.

This is a split-rated compound: ★★★★★ for the approved indication, ★★★☆☆ for off-label anti-aging use.

The mistake people make with tesamorelin is assuming that FDA approval for one thing means the evidence supports everything else it is prescribed for. The lipodystrophy data is excellent. The anti-aging data is preliminary. Both can be true.

Peptexa editorial note

FDA status

Tesamorelin is FDA-approved as Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It is a prescription medication.

Off-label prescribing for anti-aging, body composition, and cognitive enhancement is legal but physician-directed. Insurance typically does not cover off-label use. Last reviewed 2026-08-19.

Common synonyms researchers use

Tesamorelin · Egrifta · TH9507 · GHRH(1-44)NH2 · Growth hormone-releasing factor analog. Manufacturer: Theratechnologies.

Safety & adverse-event landscape

As an FDA-approved drug, tesamorelin has a well-characterized safety profile from clinical trials. Common side effects include injection site reactions, joint pain, peripheral edema, and elevated blood glucose. It is contraindicated in pregnancy and should be used cautiously in patients with active malignancy (GH stimulation may promote tumor growth).

Long-term safety beyond the clinical trial duration is being monitored through post-marketing surveillance. Elevated IGF-1 levels have theoretical implications for cancer risk. A consideration in the GH-axis literature broadly.

Peptexa is an educational resource. We do not provide dosing guidance, sourcing recommendations, or protocol advice. Always consult a qualified healthcare provider before any decision involving a peptide or therapeutic compound.

Frequently asked questions

Yes. Tesamorelin is FDA-approved as Egrifta for HIV-associated lipodystrophy. It requires a prescription. Off-label use for anti-aging is physician-directed.
No. Peptexa is educational only. We do not sell or ship any peptide product.
Tesamorelin stimulates growth hormone release and reduces visceral fat. Some preliminary data suggests cognitive and metabolic benefits in non-HIV populations. However, no large RCT has been conducted for general anti-aging use. Split evidence rating: 5 stars for the approved indication, 3 stars for anti-aging.
Tesamorelin stimulates your pituitary to release growth hormone in a more natural pulsatile pattern. Direct GH injection delivers supraphysiological GH levels. Tesamorelin preserves feedback regulation; direct GH injection bypasses it.
Tesamorelin raises IGF-1 levels, which has theoretical implications for cancer risk. A topic debated in the growth hormone literature broadly. It is contraindicated in patients with active malignancy. Long-term risk data from post-marketing surveillance is ongoing.

Related on Peptexa

Sermorelin: what the science actually shows Ipamorelin: what the science actually shows MK-677: what the science actually shows Take the peptide quiz

Want this in your inbox weekly?

Get the Peptexa Top-5 free, five compounds, mechanism-led. One email a week. No spam.

The full Anti-Aging & Longevity reference

32 compounds. Mechanism, evidence level, and regulatory status for every one.

Get the Anti-Aging & Longevity Guide →